Suggestions
Karin Hehenberger
President at Lyfebulb, Chief Medical Officer, Patient Care America, Health care executive, Patient leader, Independent board member
Karin Hehenberger is a prominent figure in the life sciences sector, currently serving as the President of Lyfebulb and the Chief Medical Officer at Patient Care America. With nearly 25 years of experience, she has held significant roles in various organizations, including Eyetech Pharmaceuticals and Coronado BioSciences, and has had strategic positions at Johnson & Johnson and JDRF (Juvenile Diabetes Research Foundation) .123
Education and Early Career
Dr. Hehenberger earned her MD and PhD from the Karolinska Institute and completed a post-doctoral fellowship at the Joslin Diabetes Center, affiliated with Harvard Medical School. Her early career included senior roles in management consulting at McKinsey and partnership positions in investment funds focused on life sciences .12
Contributions to Patient Care
At Lyfebulb, she focuses on empowering patients with chronic diseases through innovative solutions. Her leadership aims to enhance patient engagement and improve health outcomes .13 Additionally, her work at Patient Care America emphasizes personalized care strategies, particularly for individuals with diabetes .12
Personal Insights
Dr. Hehenberger's personal experiences with type 1 diabetes have profoundly influenced her professional journey, driving her commitment to patient advocacy and empowerment in healthcare .14
Highlights
Today we issued a report together with Renalogic, describing the unpredictable nature of how patients experience dialysis in the United States.
Alarmingly, 62% of dialysis treatments were unplanned, which shows the unpredictability and disruption of CKD. Over half (54%) of patients reported having to stop work while on dialysis and 50% had visited the emergency room or been hospitalized in the past year.
Dialysis should be a planned treatment following the diagnosis of end stage renal disease, and only in exceptional cases be the result of an emergency room visit. Optimally dialysis is a bridge to transplant, but for a majority of Americans, dialysis is the final destination.
We need to work harder at increasing the number of organs available, keeping the kidney grafts alive longer and optimizing the care of transplant patients and those on dialysis. #dialysis #transplant #kidneydisease #drugdevelopment #patientcare
Kevin Weinstein Leslie Simmons Brille Lyfebulb DaVita Kidney Care Fresenius Medical Care Eledon Pharmaceuticals, Inc. ITB-MED Veloxis Pharmaceuticals, Inc. CareDx, Inc. Eurofins Bristol Myers Squibb Sanofi Jamie Haight Patient Care America Tim Fitzpatrick Phil Keough
We are excited to announce the winner of the inaugural JPM Asset Management Life Sciences Innovation Summit as Rayees R. of Harmonic Discovery as well as our runner-up Chun-Hao Huang of Algen Biotechnologies.
Dr Steve Squinto and his team at the JPM Life Sciences Private Capital group originating the idea to source global talent to continue to grow the emerging biotech hub in the Emirati region close to one year ago. Together as a team, we completed the challenge over the past few days in Abu Dhabi. This is only the beginning of what will come!
Thank you to our partner the Department of Health Abu Dhabi, our lead sponsor Blue Horizon / United Al Saqer Group as well as our supporters Thermo Fisher Scientific, Salam Capital and JPM commercial bank. We were graciously hosted by Cleveland Clinic Abu Dhabi which showcased its world class patient care and science to all finalists.
All finalists presented compelling cases of innovation and ability to address unmet needs, but what stood out in our winners were the clear case of how to improve patient care in the Emirati region and the innovative level of the technology.
Thank you also to our experienced judges Dr Laurie Glimcher (CEO Dana Farber), Dr Shahrukh Hashmi (DOH Abu Dhabi), Dr Yasmine Hayek Kobeissi Ph.D (Blue Horizon), Dr Jorge A. Guzman (CEO Cleveland Clinic Abu Dhabi), Anya Schiess (JPM) and Dr Zaher Walid Zaher (CEO CareXso).
Nabil Kobeissi and his team at Blue Horizon/United Al Saquer group surprised the group by announcing the intention of BHA to invest in the winner of the challenge as well as to evaluate all finalists for further commitments. Masdar City provided business licenses to all finalists so that they can set up offices in the region.
https://lnkd.in/e6CmvPG2
#innovation #biotech #lifesciences #emirati #sicklecelldisease #crispr #ai #oncology
Stephen Squinto Gaurav Gupta Department of Health Abu Dhabi Dana-Farber Cancer Institute Lyfebulb Leslie Simmons Brille Jamie Haight Olivia Schwern Joanna Rowe Evan Sotiriou Abby Mueller Patrik Strömberg Natalie J. Galant, PhD Seah Lim Cesare Spadoni Patient Care America Dongxing Zha Jaden Hyungseok C. Matthew Lorence Anton Malyshev SaudiVax Mohamed Mostafa
